Hangzhou TianMuShan Pharmaceutical Enterprise ,Ltd Receivables

As of the most recent data (June 2026), 600671.SS shows a receivables of $130M. That compares with $120M in the prior-year period — up 12.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 600671.SS's receivables is now $130M (was $120M) — a 12.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Hangzhou TianMuShan Pharmaceutical Enterprise ,Ltd is outperforming or lagging.

Tracking 600671.SS's receivables over time shows whether Hangzhou TianMuShan Pharmaceutical Enterprise ,Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $120M in the prior-year period — up 12.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Hangzhou TianMuShan Pharmaceutical Enterprise ,Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130M) with ownership activity and broader fundamentals.